6WYR
 
 | | Crystal structure of anti-Muscle Specific Kinase (MuSK) Fab, MuSK1A | | Descriptor: | 1,2-ETHANEDIOL, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, MuSK1A heavy chain, ... | | Authors: | Vieni, C, Ekiert, D. | | Deposit date: | 2020-05-13 | | Release date: | 2020-07-29 | | Last modified: | 2023-10-18 | | Method: | X-RAY DIFFRACTION (1.8 Å) | | Cite: | Affinity maturation is required for pathogenic monovalent IgG4 autoantibody development in myasthenia gravis.
J.Exp.Med., 217, 2020
|
|
6WYT
 | |
2MSD
 | | NMR data-driven model of GTPase KRas-GNP tethered to a lipid-bilayer nanodisc | | Descriptor: | 1,2-DIOLEOYL-SN-GLYCERO-3-PHOSPHOCHOLINE, Apolipoprotein A-I, GTPase KRas, ... | | Authors: | Mazhab-Jafari, M, Stathopoulos, P, Marshall, C, Ikura, M. | | Deposit date: | 2014-07-29 | | Release date: | 2015-06-03 | | Last modified: | 2019-12-11 | | Method: | SOLUTION NMR | | Cite: | Oncogenic and RASopathy-associated K-RAS mutations relieve membrane-dependent occlusion of the effector-binding site.
Proc.Natl.Acad.Sci.USA, 112, 2015
|
|
2MSE
 | | NMR data-driven model of GTPase KRas-GNP:ARafRBD complex tethered to a lipid-bilayer nanodisc | | Descriptor: | 1,2-DIOLEOYL-SN-GLYCERO-3-PHOSPHOCHOLINE, Apolipoprotein A-I, GTPase KRas, ... | | Authors: | Mazhab-Jafari, M, Stathopoulos, P, Marshall, C, Ikura, M. | | Deposit date: | 2014-07-29 | | Release date: | 2015-06-03 | | Last modified: | 2019-12-11 | | Method: | SOLUTION NMR | | Cite: | Oncogenic and RASopathy-associated K-RAS mutations relieve membrane-dependent occlusion of the effector-binding site.
Proc.Natl.Acad.Sci.USA, 112, 2015
|
|
2MSC
 | | NMR data-driven model of GTPase KRas-GDP tethered to a lipid-bilayer nanodisc | | Descriptor: | 1,2-DIOLEOYL-SN-GLYCERO-3-PHOSPHOCHOLINE, Apolipoprotein A-I, GTPase KRas, ... | | Authors: | Mazhab-Jafari, M, Stathopoulos, P, Marshall, C, Ikura, M. | | Deposit date: | 2014-07-29 | | Release date: | 2015-06-03 | | Last modified: | 2019-12-11 | | Method: | SOLUTION NMR | | Cite: | Oncogenic and RASopathy-associated K-RAS mutations relieve membrane-dependent occlusion of the effector-binding site.
Proc.Natl.Acad.Sci.USA, 112, 2015
|
|
